AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Genetics of Cancer

November 4-8, 1992
Marriott Hilton Head Resort, Hilton Head, South Carolina

Supported by a Generous Grant from
the General Motors Cancer Research Foundation

CONFERENCE CO-CHAIRPERSONS

Webster K. Cavenee / La Jolla, CA
Raymond L. White / Salt Lake City, UT

SCIENTIFIC PROGRAM

Keynote Address
Robert A. Weinberg / Cambridge, MA

Inherited Cancer Genes
Bruce A.J. Ponder / Cambridge, England
Raymond L. White / Salt Lake City, UT
Frank McCormick / Emeryville, CA
Arnold J. Levine / Princeton, NJ
Webster K. Cavenee / La Jolla, CA

Genetic Mechanisms
Carmen Sepienza / La Jolla, CA
Carlo M. Croce / Philadelphia, PA
Neal G. Copeland / Frederick, MD

Molecular Genetics of Mitosis
George F. Vande Woude / Frederick, MD
Carol Greider / Cold Spring Harbor, NY
Andrew Murray / San Francisco, CA
David Beach / Cold Spring Harbor, NY
Erich A. Nigg / Lausanne, Switzerland

Genetic Instability
Geoffrey Wahl / San Diego, CA
C. Thomas Caskey / Houston, TX
Walton Fangman / Seattle, WA

Genetics and Cell Commitment
Stuart A. Aaronson / Bethesda, MD
Mariano Barbacid / Princeton, NJ
M. Geoffrey Rosenfeld / La Jolla, CA
David Anderson / Pasadena, CA
Leo Sachs / Rehovot, Israel

Animal Models
Mario Capecchi / Salt Lake City, UT
Douglas Hanahan / San Francisco, CA
Erwin Wagner / Vienna, Austria

Programmed Cell Death
Stanley J. Korsmeyer / St. Louis, MO
H. Robert Horvitz / Cambridge, MA
John T. Isaacs / Baltimore, MD
Peter Kramer / Heidelberg, Germany

Information and Application Forms

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483

215-440-9300 215-440-9313 (FAX)

Application Deadline: August 10, 1992
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Molecular and Biochemical Methods in Cancer Epidemiology and Prevention - The Path Between the Laboratory and the Population

September 23-26, 1992
The Registry Resort, Naples, Florida

CONFERENCE CHAIRPERSON
David Schottenfeld / Ann Arbor, MI

PROGRAM COMMITTEE
Myron Essex / Boston, MA
Curtis C. Harris / Bethesda, MD
Thomas E. Moon / Tucson, AZ
Stephen S. Hecht / Valhalla, NY
Barbara S. Hulka / Chapel Hill, NC
Lewis H. Kuller / Pittsburgh, PA
Mortimer L. Mendelsohn / Livermore, CA
Paul A. Schulte / Cincinnati, OH

SCIENTIFIC PROGRAM

Keynote Addresses
Paul A. Schulte / Cincinnati, OH
Mortimer L. Mendelsohn / Livermore, CA
Curtis C. Harris / Bethesda, MD

Assessment of Exposure to Genotoxic Agents
Stephen S. Hecht / Valhalla, NY
Steven R. Tannenbaum / Cambridge, MA
Frederica Perera / New York, NY
John D. Groopman / Baltimore, MD
Gerald N. Wogan / Cambridge, MA

Biological Markers of Genetic Susceptibility
Louise C. Strong / Houston, TX
Bruce A.J. Ponder / Sutton, England
Mark Leppert / Salt Lake City, UT
Kenneth H. Buettow / Philadelphia, PA

Viral Agents
Myron Essex / Boston, MA
W. Thomas London / Philadelphia, PA
Wayne D. Lancaster / Detroit, MI
Mark Schiffman / Bethesda, MD
Nancy E. Mueller / Boston, MA

Dietary Biomarkers in Preventive Intervention Studies
Thomas E. Moon / Tucson, AZ
John D. Potter / Minneapolis, MN
Gladys Block / Bethesda, MD
David P. Rose / Valhalla, NY

Measurement of Endogenous Sex Steroid Hormones in Breast and Prostate Neoplasia
Lewis H. Kuller / Pittsburgh, PA
James Gutai / Detroit, MI
David Schottenfeld / Ann Arbor, MI

Disorders of Immune Function in Human Carcinogenesis
Charles Rabkin / Bethesda, MD
Ian T. Magrath / Bethesda, MD
David T. Purtilo / Omaha, NE

Evaluation of the Applications of Biochemical and Molecular Markers in Epidemiological Studies
Barbara S. Hulka / Chapel Hill, NC
Neil E. Caporaso / Bethesda, MD
Nathaniel Rothman / Bethesda, MD
Arthur Schatzkin / Bethesda, MD
Mark Schiffman / Bethesda, MD

Information and Application Forms
American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483

215-440-9300 215-440-9313 (FAX)
PROLEUKIN® (Alefacept)

Briefer Prescribing Information

For full prescribing information, see Package insert.

![Image]

**WARNINGS**

- **PROLEUKIN** (alefacept) injection should be administered only by or under the supervision of a physician experienced in the use of an antineoplastic agent. For some patients, severe reactions may require that an emergency team be held in developing patients to moderate severe or mortality, continued administration may result in coma.

- **INDICATIONS AND USAGE**

  - **PROLEUKIN** is indicated for the treatment of adults (18 years of age and over) with metastatic renal cell carcinoma.

  - **CONTRAINDICATIONS**

    - Patients with a history of malignancy of the eye.

    - **WARNINGS**

      - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.

  - **ADVERSE REACTIONS**

    - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.

  - **PRECAUTIONS**

    - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.

  - **CONTRAINDICATIONS**

    - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.

  - **ADVERSE REACTIONS**

    - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.

  - **PRECAUTIONS**

    - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.

  - **CONTRAINDICATIONS**

    - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.

  - **ADVERSE REACTIONS**

    - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.

  - **PRECAUTIONS**

    - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.

  - **CONTRAINDICATIONS**

    - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.

  - **ADVERSE REACTIONS**

    - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.

  - **PRECAUTIONS**

    - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.

  - **CONTRAINDICATIONS**

    - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.

  - **ADVERSE REACTIONS**

    - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.

  - **PRECAUTIONS**

    - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.

  - **CONTRAINDICATIONS**

    - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.

  - **ADVERSE REACTIONS**

    - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.

  - **PRECAUTIONS**

    - **Disseminated performance**

      - **Reactions**

    - **PROLEUKIN** is contraindicated in patients with a known history of hypertension or hypotension to 8 or any component of the PROLEUKIN formula.
Alcoholic beverages such as wine and beer have been consumed since antiquity. Distilled spirits were produced as early as the 4th century B.C., but they became available broadly only in the last few centuries as part of the Industrial Revolution. [Alcohol consumption is the subject of a detailed review in International Agency for Research on Cancer (IARC), Monograph 44, 1988.]


Dr. Ernst L. Wynder (Cancer Res., 35: Cover 2, 1975)


Cancer of the large bowel is generally associated with a high fat, low fiber nutritional regimen. However, cancer of the rectum also occurs more frequently in regular drinkers. Alcohol use may account for rectal, but not colon, cancer in populations, like that of Japan, on a low fat diet. Dr. Seitz (Alcoholism: A Molecular Perspective. New York: Plenum Publishing Corp., 1991) has contributed much to the understanding of the relevant mechanism. In laboratory rodents, alcohol increases the rate of cell replication in the rectum (Gut, 27: 278, 1986). Acetaldehyde, a reactive metabolite of alcohol, was also present in the rectum (Gastroenterology, 98: 1 and 406, 1990). This particular mechanism may also apply to the esophagus. Thus, the effect of alcohol and acetaldehyde involves several mechanisms, including the induction of enzymes and nutritional deficiencies, especially of vitamin A, and also cytotoxicity, promotion, and increased cell replication. In the presence of carcinogens, such as those from tobacco, alcohol can act as a cocarcinogen.

The research featured has been recognized by a number of awards to the individuals described.

Charles S. Lieber, M.D. (upper left), is Professor of Medicine and Pathology, Mount Sinai School of Medicine, and Director of the Alcohol Research and Treatment Center and the G.I.-Liver Training Program at the Bronx VA Medical Center, New York, New York. Dr. Lieber has authored over 700 scientific publications and five books dealing with the roles of nutrition and toxic factors in the pathogenesis of alcoholic liver disease. He is the recipient of the Hugh R. Butt Award for Clinical Research in Liver and Nutrition, given by the American Gastroenterological Association.

Helmut Karl Seitz, M.D. (lower right), is Professor of Medicine at the University of Heidelberg and Director of the Department of Internal Medicine, Salem Medical Center, Heidelberg, Germany. He has published over 150 papers and edited two books.

Albert Tuyns, M.D. (middle), officially retired in 1982, but he maintains his affiliation with the IARC, Lyon, France. Among his accomplishments of continuing value are the establishment of Cancer Registries in Europe, especially in Latin countries, and the development of World Health Organization and IARC monographs and teaching manuals.

John H. Weisburger